Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-543-5 | CAS number: 62-56-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- no data
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: case study; single patient
Data source
Reference
- Reference Type:
- publication
- Title:
- Thiourea causing granulopenia and thrombopenia.
- Author:
- Newcomb, P. B. and Deane, B. W.
- Year:
- 1 944
- Bibliographic source:
- Lancet 243 (6284):179
Materials and methods
- Study type:
- clinical case study
- Endpoint addressed:
- repeated dose toxicity: oral
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- oral application of thiourea as thyroid depressant
Test material
- Reference substance name:
- Thiourea
- EC Number:
- 200-543-5
- EC Name:
- Thiourea
- Cas Number:
- 62-56-6
- Molecular formula:
- CH4N2S
- IUPAC Name:
- thiourea
- Test material form:
- solid
- Details on test material:
- carbon atom in thiourea was radiolabelled
Constituent 1
Method
- Type of population:
- general
- Subjects:
- - Number of subjects exposed: 1
- Sex: female
- Age: 44
- Known diseases: admitted to hospital complaining of nervousness, sweating, palpitations and hot flushes which had' been getting worse for the last year. She had been given medicine for " thyroid trouble " 3 years before;
moderately severe degree of thyrotoxicosis, with the nervous elements more in evidence than the cardiovascular signs; very emotional; skin was flushed and moist; pulse-rate 100 per min; well-marked bilateral exophthalmos with some conjunctival injection; diffuse enlargement of the thyroid which was smooth and firm
Other: Treatment was started with a phenobarbitone and bromide mixture for a week, and during this time the pulse rate varied between 100 and 84 per min. - Ethical approval:
- not applicable
- Route of exposure:
- oral
- Reason of exposure:
- intentional
- Exposure assessment:
- not specified
- Details on exposure:
- 1. Dosage: 1 gramme (3x per day) for 3 weeks. During this time teh patient remained well apart from a mild attack of influenza which was then epidemic. The fever lasted for 4 days.
About 10 days after thiourea had been started the signs of hyperthyroidism began gradually to improve (patient became less emotional and the pulse settled to a constant rate of about 80 a minute.
2. Dosage: 1 g. (twice a day) for 1 week
3. Dosage: 1 g. daily, during which time the improvement was maintained although it was not as great as might have been expected fromiodine.
Results and discussion
- Clinical signs:
- A fortnight after the drug had been started a leucocyte.count 'showed a total of 9200 with 70% granulocytes and a normal differential count.
After a total of 83 g. had been given-i.e., after 5 weeks treatment with thiourea—the patient suddenly had two epistaxes and then developed generalised purpura and ecchymoses with purpuric spots on the buccal mucous membrane which ruptured leaving painful ulcers. The spleen was not palpable.
Thiourea was immediately stopped and next day the ecchymoses had become more numerous and there was bleeding from the gums. A blood-count at this time showed red cells 4,500,000 per c.mm.; Hb. 87%; white cells4100 perc.mm. with 24% granulocytes. The platelet count was 18,000. Bleeding time was greatly prolonged and even at the end of 4 hours the bleeding from the puncture wound showed no signs of stopping. Coagulation-time was normal. Sternal puncture showed a marrow which was quite cellular ; the differential count showed 7% polymorphs, 16% lymphocytes, 44% myelocytes, 10.5% myeloblasts; there were 39% erythroblasts and 48% normoblasts. Platelets were scanty and 2 megakaryocytes were seen. Since many myelocytes were present the prognosis was thought to be good. By the second day after the purpura was first observed the leucocytes had fallen to 3700 per c.mm. with 16% polymorphs, and there were only 9000 platelets. The patient was therefore transfused with a pint of fresh whole blood and all bleeding from the gums ceased 10 minutes after the transfusion had started. Pentnucleotide, 10 c.cm. (twice daily), was also started but was discontinued after six doses because it caused some pyrexia.
Subsequent blood-counts have shown a gradual return to normal, and the latest count taken 12 days after the appearance of the purpura showed a leucocyte-count of 6200 per c.mm. with 36% granulocytes, and 67,000 platelets per c.mm. The purpura and ecchymoses have faded and there has been no further hremorrhage.
During the time this patient was in hospital no other drugs were given and it seems fairly certain that the toxic effects were due to thiourea.
Any other information on results incl. tables
A female patient was treated for hyperthyroidism with 85g Thiourea for 5 weeks (1-3g/d; 20-60 mg/kg/d) without adverse effects. After 5 weeks significant side effects were reported (blood count, hemorrhage, granulocytopenia), which showed a gradual return to normal within 12 days.
Applicant's summary and conclusion
- Conclusions:
- A female patient was treated for hyperthyroidism with 85g Thiourea for 5 weeks (1-3g/d; 20-60 mg/kg/d) without adverse effects. After 5 weeks significant side effects were reported (blood count, hemorrhage, granulocytopenia), which showed a gradual return to normal within 12 days.
- Executive summary:
A female patient was treated for hyperthyroidism with 85g Thiourea for 5 weeks (1-3g/d; 20-60 mg/kg/d) without adverse effects. After 5 weeks significant side effects were reported (blood count, hemorrhage, granulocytopenia), which showed a gradual return to normal within 12 days.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.